secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001490978-25-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q1 total revenue $59.6M (+63% YoY); software rev $48.8M; maintains FY guidance
--------------------------------------------------------------------------------

- Software revenue $48.8M (+46% YoY); drug discovery revenue $10.7M (+237%) incl $5.7M from Novartis collaboration.
- GAAP net loss $59.8M vs $54.7M; non-GAAP net loss improved to $46.7M from $62.4M.
- FY 2025 guidance reaffirmed: software rev growth 10-15%, drug discovery rev $45-50M, opex growth <5%.
- Initial Phase 1 data for SGR-1505 (MALT1 inhibitor) expected in June; SGR-2921 (CDC7) and SGR-3515 (Wee1/Myt1) data in H2 2025.
- Bridget van Kralingen appointed to Board of Directors; predictive toxicology initiative on track for H2 2025 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/0001490978-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/sdgr-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001490978-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer